Hot News: FireEye, Inc. (NASDAQ:FEYE), Zynerba Pharmaceuticals (NASDAQ:ZYNE), Bridgeline Digital, Inc. (NASDAQ:BLIN), Chevron Corporation (NYSE:CVX), Genetic Technologies Limited (NASDAQ:GENE)

On 30 July, FireEye, Inc. (NASDAQ:FEYE) reported Deferred revenue totaled $409.9 million at the end of the second quarter, an increase of $177.9 million, or 77 percent, from the end of the second quarter of 2014. Current deferred revenue was $232.5 million, an increase of $95.7 million from the end of the second quarter of 2014, and included $9.2 million in deferred product revenue and $223.3 million in deferred subscription, support and services revenue. FireEye, Inc. (NASDAQ:FEYE) belongs to Technology sector. Its net profit margin is -93.10% and weekly performance is -6.27%. On last trading day company shares ended up $44.56. FireEye, Inc. (NASDAQ:FEYE) distance from 50-day simple moving average (SMA50) is -8.63%.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) said Tuesday that it has priced its initial public offering of 3 million shares at $14.00 per share, which is the mid-point of the previously estimated price range of $13.00 and $15.00 per share. Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares increased 16.07% in last trading session and ended the day at $16.25.

Zacks upgraded shares of Bridgeline Digital (NASDAQ:BLIN) from a sell rating to a hold rating in a report released on Tuesday, MarketBeat.com reports. On 05 August, Bridgeline Digital, Inc. (NASDAQ:BLIN) shares decreased -13.64% and was closed at $1.33. BLIN EPS growth in last 5 year was -46.10%. Bridgeline Digital, Inc. (NASDAQ:BLIN) year to date (YTD) performance is -42.17%.

On 31st July, Chevron Corporation (NYSE:CVX) reported earnings of US$571 million (US$0.30 per share – diluted) for 2Q15, compared with earnings of US$5.7 billion (US$2.98 per share – diluted) in 2Q14. Included in the quarter were impairments of US$1.96 billion and other charges of approximately US$670 million relating to project suspensions and adverse tax effects, all of which were non-cash charges stemming from a downward revision in the company’s longer term crude oil price outlook. Chevron Corporation (NYSE:CVX) ended the last trading day at $84.03. Company weekly volatility is calculated as 2.58% and price to cash ratio as 12.06. Chevron Corporation (NYSE:CVX) showed a weekly performance of -9.89%.

Genetic Technologies Limited (NASDAQ:GENE) shares decreased -5.72% in last trading session and ended the day at $2.80. GENE Gross Margin is 60.70% and its return on assets is -244.80%. Genetic Technologies Limited (NASDAQ:GENE) quarterly performance is -36.07%.

Leave a Reply

Your email address will not be published. Required fields are marked *